Release Date:

December 13, 2013

Expiration Date:

December 31, 2014

Estimated time to complete activity:

1.25 hours

Faculty

Michael B. Bottorff, PharmD, FCCP, FNLA, CLS, Chair
Professor and Chair, Department of Pharmacy Practice
School of Pharmacy
South College
Knoxville, TN

Gregory S. Pokrywka, MD, FACP, FNLA, NCMP
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Director, Baltimore Lipid Center
Diplomate, American Board of Clinical Lipidology
Baltimore, MD

Target Audience:

Managed Care/Retail Pharmacists, Physicians, and other healthcare professionals involved in the care of patients with elevated triglycerides and cardiovascular comorbidities

Program Overview:

The pharmacist’s increasing and evolving role in Medication Therapy Management for patients with dyslipidemia and elevated cardiovascular disease (CVD) risk supports the need for education regarding the role triglycerides (TGs) play in CV health. Typically, efforts to control dyslipidemia have focused on lowering low-density lipoprotein cholesterol (LDL-C). However, despite aggressive LDL-C lowering with statin therapy, a large residual CVD risk remains. This online activity, based on a live meeting on October 17, 2013 in San Antonio, TX, focuses on the important role of hypertriglyceridemia (HTG) as a CVD risk factor and the management of HTG.

Learning Objectives

After completing this activity, the participant should be better able to:

• Identify the significance of elevated TGs as a risk factor in CV disease and other health conditions related to dyslipidemia
• Review recommended methods of monitoring TG levels, including how to determine elevations in TGs relative to other lipid levels
• Describe the pharmacist’s role in managing patients with dyslipidemia
• Expand the pharmacist’s patient-counseling skills to improve outcomes in lipid management
• Assess available clinical trial data on agents used to modify TG levels and describe appropriate use of these agents in patients with elevated TGs
• Provide accurate and appropriate counsel as part of the treatment team

Physician Continuing Education

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and Medtelligence, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour (0.125 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0809-9999-13-341-H01-P)

Type of Activity:

Application

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Michael B. Bottorff, PharmD: Consulting Fees: Boehringer Ingelheim; Fees for Non-CME/CE Services: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer

Gregory S. Pokrywka, MD: Consulting Fees: Aegerion, Amarin, Novartis; Fees for Non-CME/CE Services: Aegerion, Amarin, AstraZeneca, Genzyme, Kowa, Sanofi

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Medtelligence, LLC: Ben Caref, PhD; Pamela Clark - No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Method of Participation and Request for Credit

There are no fees for participating and receiving CME credit for this activity. During the period December 13, 2013 through December 31, 2014, participants must read the learning objectives and faculty disclosures and study the educational activity.

To receive credit, you must:

• Review the full content of the program
• Successfully complete the post-test (70% or higher)
• You will have 3 opportunities to successfully complete the program

Your statement of credit will be issued immediately upon successful completion of the test and submission of the evaluation form.

Media:

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Sponsorship

This activity is jointly sponsored by Postgraduate Institute for Medicine and Medtelligence, LLC
  

Commercial Support

Supported by an educational grant from Amarin Pharma Inc